You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. RestEaze: A Novel Wearable Device and Mobile Application to Improve the Diagnosis and Management of Restless Legs Syndrome in Pediatric Patients with Attention Deficit/Hyperactivity Disorder

    SBC: TANZEN MEDICAL, INC.            Topic: 104

    Project Abstract Millions of pediatric patients with attention-deficit/hyperactivity disorder (ADHD) suffer from sleep disturbances that significantly degrade their quality of life and amplifies the heavy emotional and financial burden on caregivers. Restless Legs Syndrome (RLS) is a likely (and treatable) factor for the sleep disturbance in these patients. Oral iron therapy has been shown to impr ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis

    SBC: Rise Therapeutics, LLC            Topic: NIA

    Project Summary Our goal is to develop a novel, immunological-directed L. lactis probiotic-based therapeutic for the treatment of rheumatoid arthritis (RA). RA is a chronic, systemic inflammatory disorder affecting up to 1% of the US population1, 2. While many organs are affected in RA, the synovial joints are primarily afflicted with debilitating inflammation. Approximately half of all RA patient ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone disease

    SBC: Nostopharma, LLC            Topic: 300

    There is a critical need to improve drug development strategies for rare diseases, as more than 7000 rare and neglected diseases currently have no treatments available. At the same time, as new drug therapies remain costly and time-consuming, repositioning existing drugs and drug candidates offers an alternative approach to developing therapeutics for rare diseases. Nostopharma seeks to address th ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Intraoperative Pulsed Field Ablation and Lesion Assessment System

    SBC: SIGT, LLC            Topic: NHLBI

    Over 6 million Americans suffer from atrial fibrillation (AF), which negatively impacts their quality of life and is associated with high morbidity and mortality. Pulsed Electric Field Ablation (PFA) has emerged as a promising; non-thermal, tissue-specific ablation modality for treatment of AF. During PFA, trains of ultrashort (µs duration) high voltage (~2KV) electric pulses are delivered to the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease

    SBC: ABVACC, INC.            Topic: NIAID

    Project Summary Ebola (EBOV) and Marburg (MARV) viruses cause hemorrhagic fever disease in humans and nonhuman primates (NHPs) with case-fatality rates as high as 90%. The 2013-2016 Ebola Virus Disease (EVD) outbreak led to over 28,000 cases and 11,000 deaths and took an enormous toll on the economy of West African nations, in the absence of any vaccine or therapeutic options. This outbreak spurre ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro

    SBC: SANARIA INC.            Topic: NIAID

    In 2022 WHO called for highly efficacious vaccines against malaria that prevent Plasmodium falciparum (Pf) infection in rt 90% of recipients. Alone among malaria vaccines, Sanaria® PfSPZ (Pf sporozoite (SPZ)) vaccines have shown rt 90% vaccine efficacy (VE) against controlled human malaria infection and VE against intense field transmission of malaria to pregnant women for two transmission years ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD

    SBC: CREATIVE BIO-PEPTIDES INC            Topic: NIA

    7. Project Summary ADRD dementias account for up to 25% of all dementias in patients older than 65 years and there is strong evidence of co-morbid pathologies caused by (amyloid β (Aβ), tau and α-synuclein (αSyn). The degree of AD- related pathology in Lewy Body Dementias (LBD) is moderate or severe in 50% of PDD and more than 70% of DLB patients have concomitant AD-related pathology so that t ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options

    SBC: Golden Helix, Inc.            Topic: 172

    Abstract Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has undergone rapid advancements. This has occurred alongside a decrease in the cost of genotyping technology, making implementation of pharmacogenomics into clinical practice increasingly feasible. Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.

    SBC: DERMAXON LLC            Topic: NIAMS

    Project Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (atRA) in the epidermis, as an oral treatment for severe recalcitrant acne. This approach will provide an improved acne therapeutic without the adverse effects associated with currently marketed retinoid ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development and Evaluation of Portable Compendium of Psychophysical and Physiological Tests for Alzheimer's Disease and Related Dementias (ADRD)

    SBC: EVON MEDICS LLC            Topic: NIA

    ABSTRACT The Development and Evaluation of Portable Compendium of Psychophysical and Physiological Tests for Alzheimer’s Disease and Related Dementias (ADRD) is a project to develop an inexpensive, user-friendly, digital chemosensory-sensorimotor acquisition and processing device, with cross-cultural validity for home or office use for automated (a) staging of severity of age-related cognitive d ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government